Vincerx Pharma Stock Performance
| VINC Stock | USD 0.62 0.01 1.59% |
The entity has a beta of -1.65, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Vincerx Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Vincerx Pharma is expected to outperform it. At this point, Vincerx Pharma has a negative expected return of -2.42%. Please make sure to validate Vincerx Pharma's skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Vincerx Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Vincerx Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1 | Insider Trading | 12/20/2024 |
2 | Acquisition by Seelenberger Alexander A. of 58000 shares of Vincerx Pharma at 1.71 subject to Rule 16b-3 | 12/27/2024 |
3 | Vincerx Pharma, Inc. Short Interest Update | 01/14/2025 |
4 | Vincerx Pharma, Inc. Announces Reverse Stock Split | 01/23/2025 |
5 | Palo Altos Vincerx Pharma plans reverse stock split amid merger plans | 01/24/2025 |
6 | Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqorys TROP2 Antibody Drug Conjugate, OQY-3258 | 01/29/2025 |
7 | Vincerx Pharma, Inc. Short Interest Update - MarketBeat | 01/30/2025 |
8 | Acquisition by Seelenberger Alexander A. of 200000 shares of Vincerx Pharma at 0.55 subject to Rule 16b-3 | 01/31/2025 |
9 | Acquisition by Lowe Christopher P. of 18400 shares of Vincerx Pharma at 1.6467 subject to Rule 16b-3 | 02/06/2025 |
10 | US Stocks Likely To Open Higher As Wall Street Watches TruTariff Talks March, April, May Tend To Be Solid Months In Post-Election Years, Says Expert | 03/03/2025 |
11 | Acquisition by Hamdy Ahmed Md of 60000 shares of Vincerx Pharma subject to Rule 16b-3 | 03/13/2025 |
12 | Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI | 03/18/2025 |
| Begin Period Cash Flow | 11.7 M |
Vincerx |
Vincerx Pharma Relative Risk vs. Return Landscape
If you would invest 396.00 in Vincerx Pharma on December 21, 2024 and sell it today you would lose (334.00) from holding Vincerx Pharma or give up 84.34% of portfolio value over 90 days. Vincerx Pharma is currently does not generate positive expected returns and assumes 12.4677% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Vincerx, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vincerx Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vincerx Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vincerx Pharma, and traders can use it to determine the average amount a Vincerx Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.194
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VINC |
Estimated Market Risk
| 12.47 actual daily | 96 96% of assets are less volatile |
Expected Return
| -2.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vincerx Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vincerx Pharma by adding Vincerx Pharma to a well-diversified portfolio.
Vincerx Pharma Fundamentals Growth
Vincerx Stock prices reflect investors' perceptions of the future prospects and financial health of Vincerx Pharma, and Vincerx Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vincerx Stock performance.
| Return On Equity | -1.42 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | (7.03 M) | ||||
| Shares Outstanding | 30.88 M | ||||
| Price To Book | 0.16 X | ||||
| EBITDA | (42.61 M) | ||||
| Net Income | (40.16 M) | ||||
| Cash And Equivalents | 80.86 M | ||||
| Cash Per Share | 3.82 X | ||||
| Total Debt | 2.5 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 7.88 X | ||||
| Book Value Per Share | 0.52 X | ||||
| Cash Flow From Operations | (40.45 M) | ||||
| Earnings Per Share | (1.14) X | ||||
| Market Capitalization | 10.48 M | ||||
| Total Asset | 18.22 M | ||||
| Retained Earnings | (159.11 M) | ||||
| Working Capital | 9.13 M | ||||
About Vincerx Pharma Performance
By analyzing Vincerx Pharma's fundamental ratios, stakeholders can gain valuable insights into Vincerx Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vincerx Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vincerx Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (433.10) | (454.76) | |
| Return On Tangible Assets | (2.54) | (2.41) | |
| Return On Capital Employed | (3.89) | (3.69) | |
| Return On Assets | (2.54) | (2.41) | |
| Return On Equity | (4.12) | (3.91) |
Things to note about Vincerx Pharma performance evaluation
Checking the ongoing alerts about Vincerx Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vincerx Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vincerx Pharma generated a negative expected return over the last 90 days | |
| Vincerx Pharma has high historical volatility and very poor performance | |
| Vincerx Pharma has some characteristics of a very speculative penny stock | |
| Vincerx Pharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (40.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vincerx Pharma currently holds about 80.86 M in cash with (40.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vincerx Pharma has a poor financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company outstanding shares are owned by insiders | |
| Latest headline from gurufocus.com: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI |
- Analyzing Vincerx Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vincerx Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Vincerx Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vincerx Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vincerx Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vincerx Pharma's stock. These opinions can provide insight into Vincerx Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Vincerx Stock analysis
When running Vincerx Pharma's price analysis, check to measure Vincerx Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vincerx Pharma is operating at the current time. Most of Vincerx Pharma's value examination focuses on studying past and present price action to predict the probability of Vincerx Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vincerx Pharma's price. Additionally, you may evaluate how the addition of Vincerx Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |